For research use only. Not for therapeutic Use.
Concizumab（Cat No.:I042255）is a monoclonal antibody designed to target and inhibit tissue factor pathway inhibitor (TFPI), a protein involved in regulating blood clotting. By blocking TFPI, Concizumab enhances the activation of the coagulation cascade, potentially improving clot formation. This makes it a promising therapeutic candidate for patients with hemophilia, a condition characterized by deficient blood clotting. In clinical trials, Concizumab has shown potential in preventing bleeding episodes in hemophilia patients, offering an alternative to traditional factor replacement therapies.
| CAS Number | 1312299-39-0 |
| Purity | ≥95% |
